BRIEF published on 11/06/2026 at 07:35, 8 days 3 hours ago Positive Outcomes from Aelis Farma's Retrospective Study on AEF0217 Clinical Trial Aelis Farma Cognitive Improvement AEF0217 Down Syndrome
PRESS RELEASE published on 11/06/2026 at 07:30, 8 days 3 hours ago Inside Information / Other news releases
BRIEF published on 04/07/2026 at 07:05, 7 months 7 days ago Aelis Farma Secures €458k Grant for Obesity Program France 2030 Aelis Farma Obesity Research CB1 Receptor Nouvelle-Aquitaine Grant
PRESS RELEASE published on 04/07/2026 at 07:00, 7 months 7 days ago Inside Information / Other news releases Aelis Farma receives €458k grant under France 2030 for obesity program development, reinforcing innovation potential in metabolism field Metabolic Diseases Grant France 2030 Obesity Aelis Farma
BRIEF published on 03/21/2026 at 10:10, 7 months 24 days ago Aelis Farma Advances Phase 2B Clinical Trial for Down Syndrome Treatment Clinical Trial CB1 Receptor AEF0217 Down Syndrome Adaptive Behavior
PRESS RELEASE published on 03/21/2026 at 10:05, 7 months 24 days ago Inside Information / Other news releases Aelis Farma initiates Phase 2B clinical trial with AEF0217 for Down syndrome cognitive impairments, recruiting in France, Italy, and Spain. A promising first-in-class CB1-SSi inhibitor treatment Phase 2b Aelis Farma AEF0217 Down Syndrome Cognitive Impairments
BRIEF published on 01/12/2026 at 07:35, 10 months 2 days ago Aelis Farma receives a favorable opinion from the EMA for AEF0217 in trisomy 21 EMA Aelis Farma AEF0217 Down Syndrome Pediatric Development
BRIEF published on 12/02/2025 at 07:05, 11 months 12 days ago Aelis Farma launches a Phase 2B clinical trial for AEF0217 in people with Down syndrome Clinical Trial Aelis Farma CB1-SSi AEF0217 Down Syndrome
BRIEF published on 09/25/2025 at 22:20, 1 year 1 month ago Availability of the 2025 half-year financial report by Aelis Farma Financial Report Biopharmaceuticals Aelis Farma Medical Innovations CB1-SSi
PRESS RELEASE published on 09/25/2025 at 22:15, 1 year 1 month ago Half yearly financial reports and audit reports/limited reviews / Terms of availability of the half-yearly financial report Aelis Farma announces availability of 2025 half-year financial report. Company specializes in CB1 receptor treatments for brain and peripheral diseases Financial Report Aelis Farma CB1 Receptor Brain Diseases Peripheral Diseases
Published on 11/14/2026 at 01:30, 9 hours 38 minutes ago NuRAN Wireless Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
Published on 11/14/2026 at 00:40, 10 hours 28 minutes ago BEACN Announces Annual General and Special Meeting Results
Published on 11/14/2026 at 00:35, 10 hours 33 minutes ago American Hotel Income Properties REIT LP Reports Q3 2026 Results
Published on 11/14/2026 at 00:00, 11 hours 8 minutes ago SLAM Announces Proposed Extension of Warrant Expiry Dates
Published on 11/13/2026 at 23:15, 11 hours 53 minutes ago Core Critical Metals Corp. Announces $500,000 Non-Brokered Critical Mineral Flow-Through Private Placement
Published on 11/13/2026 at 23:24, 11 hours 44 minutes ago EQS-Adhoc: ASOS PLC: Repurchase of £90m of 2028 Convertible Bonds
Published on 11/13/2026 at 21:52, 13 hours 16 minutes ago EQS-Adhoc: Airbus reports share buyback transactions 9-13 November 2026
Published on 11/13/2026 at 19:08, 15 hours 59 minutes ago EQS-Adhoc: CHAPTERS Group AG: Successful Completion of Private Placement of the Capital Increase from Authorized Capital Resolved on November 13, 2026
Published on 11/13/2026 at 18:04, 17 hours 4 minutes ago EQS-Adhoc: CHAPTERS Group AG: Capital Increase from Authorized Capital Resolved
Published on 11/13/2026 at 11:35, 23 hours 33 minutes ago ENGIE and Google to partner on energy solutions for a potential data center project near Châteauroux, France
Published on 11/12/2026 at 23:12, 1 day 11 hours ago Belgrano continues the implementation of its public share buyback offer (OPRA)
Published on 11/12/2026 at 18:36, 1 day 16 hours ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/10/2026
Published on 11/12/2026 at 18:00, 1 day 17 hours ago Information concerning the total number of voting rights and shares in the share capital as of November 12, 2026
Published on 11/12/2026 at 17:40, 1 day 17 hours ago Financial information for the period ended 30 September 2026
